Insulin Glargine (Lantus), A New Long-acting Insulin
Insulin Glargine (Lantus) is a new long-acting human insulin analog approved by the FDA for treatment of both type 1 and type 2 diabetes. Synthesized by recombinant DNA technology, it differs from human insulin at position 21 in the A-chain where asparagine is replaced by glycine and at the C-terminus of the B-chain where two arginines are added....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Insulin Glargine (Lantus), A New Long-acting Insulin
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1110
Article Code: 1110a
Date: August 6, 2001
Volume: 43
Pages: 65-66
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1110
Article Code: 1110a
Date: August 6, 2001
Volume: 43
Pages: 65-66
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)